Home Healthcare IT Global Myocardial Infarction Market Size, Share and Top Trends to 2030

Myocardial Infarction Market

Myocardial Infarction Market Size, Share & Trends Analysis Report By Product Type (Analgesics, Antiplatelet agents, Vasodilators, Thrombolytics and anti-thrombotic agents, Glycoprotein IIb/IIIa inhibitors, Β adrenergic blockers, Angiotensin receptor antagonists, Angiotensin converting enzyme inhibitors), By Distribution Channel (Hospitals, Hospital Pharmacies, Drug Stores, Online drug stores) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRHI415DR
Study Period 2018-2030 CAGR 8%
Historical Period 2018-2020 Forecast Period 2022-2030
Base Year 2021 Base Year Market Size USD 1.92 Billion
Forecast Year 2030 Forecast Year Market Size USD 3.85 Billion
Largest Market North America Fastest Growing Market Europe
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The global myocardial infarction market size was valued at USD 1.92 billion in 2021. It is estimated to reach USD 3.85 billion by 2030, growing at a CAGR of 8% during the forecast period (2022–2030).

Myocardial (MI) is a medical term for a heart attack. It occurs when blood supply from the coronary artery to the heart muscle gets blocked due to plaque buildup—the substance made up of cholesterol and fats. Sudden chest pain, shortness of breath, anxiety, and sweating are some of the most of common symptoms of MI. People with high blood pressure, obesity, diabetes, smoking addiction, and family history with heart attacks are more prone to myocardial infarction. Moreover, rising incidences of coronary artery diseases and changing lifestyle are the major contributors to the growing incidence of such as diseases. Electrocardiogram, blood tests, and coronary angiogram are few major diagnostic tests used for detection of the MI.

Market Dynamics

Increasing prevalence of cardiovascular diseases, obesity, and diabetes

According to American Heart Association (2018), 92.1 million Americans suffered from cardiovascular diseases. Cardiovascular diseases include coronary heart disease, rheumatic heart disease, and others. The most common was the coronary heart disease, which caused 43.8% deaths in the U.S. According to the Centre for Disease Control & Prevention (CDC) 2016, Women with diabetes have a 40% more risk of developing heart diseases and a 25% more risk of stroke than men with diabetes. People with diabetes are twice as likely to have MI because diabetic people have higher cholesterol & triglycerides leading to higher chance of MI.

Regional Analysis

Global Myocardial Infarction market by Americas, Asia Pacific, Europe, and the Middle East and Africa.

North America is dominating the market and accounted for the highest share in the forecast period. Increasing prevalence of cardiovascular diseases in the U.S is expected to drive the growth of the market. For instance, according to the Centre for Disease Control and Prevention (CDC), every 40 second someone gets diagnosed with myocardial infarction in the U.S. Additionally, according to American Heart Association (AHA) 2018, about 92.1 million adult Americans are living with cardiovascular diseases. These are causing more deaths than all forms of cancers and chronic respiratory diseases each year. Coronary artery disease is the leading cause of myocardial infarction, which accounts for 43.8% of deaths in the U.S. The overall prevalence of MI in the U.S is 3%. Additionally, lack of physical activity is also raising the risk of MI, and it is estimated that about 30.4% of the U.S adults do not engage themselves in any form of physical activity. Mexico is expected to emerge as slow growing market at country level owing to low government spending on healthcare and a smaller number of health workers. Additionally, it has low rates of daily smoking and alcohol consumption.

Europe is second leading region in the forecast period owing presence of leading pharmaceutical companies in the region. AstraZencea, one of the leading pharmaceutical companies, launched an app ‘Day by Day’ in partnership with mobile health enabled company Vida in 2015 and with collaboration with Duke University it helps patients to recover from the trauma of heart attack. The app provides coaching for the speedy recovery and also provide educational videos and food journals to patients.

Middle East & Africa is offering various lucrative opportunities for the market. Recently, a steep rise in the heart-related problems have been witnessed in South Africa due to growing obesity, drinking habit, inactive lifestyle, and a high number of smokers. A third of South Africans have high blood pressure, which can lead to myocardial infarction or heart failure. Additionally, hypertension is the major cause for MI. To combat this, South African heart association has provided the specific diet guidelines to the population. Thus, it expected to provide lucrative opportunities to the market players to expand their reach in this region to meet the increasing demand for myocardial Infarction treatment.

Report Scope

Report Metric Details
Segmentations
By Product Type
  1. Analgesics
  2. Antiplatelet agents
  3. Vasodilators
  4. Thrombolytics and anti-thrombotic agents
  5. Glycoprotein IIb/IIIa inhibitors
  6. Β adrenergic blockers
  7. Angiotensin receptor antagonists
  8. Angiotensin converting enzyme inhibitors
By Distribution Channel
  1. Hospitals
  2. Hospital Pharmacies
  3. Drug Stores
  4. Online drug stores
Company Profiles Apotex Inc. AstraZeneca Bayer AG Boehringer-Ingelheim Bristol-Myers Squibb Company Daiichi Sankyo Co. Ltd. Mylan N.V. Novartis AG Par Pharmaceutical Companies Inc. Pfizer Inc.
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

For a better understanding of the global myocardial infarction market, we have segmented the market by Product Type, and distribution channel.

By Product Type, the market is segmented into analgesics, antiplatelet agents, vasodilators, thrombolytics and anti-thrombotic agents, glycoprotein IIB/IIIA inhibitors, β adrenergic blockers, other. Analgesics is accounting for the largest share of the market. Analgesics are the medicine used to reduce pain. They act differently on peripheral & central nervous system. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) are a specific class of analgesic that inhibit COX enzymes and reduces pain by reducing inflammation. According to the FDA, NSAIDs can increase the risk of myocardial infarction & strokes. Therefore, they are properly labeled. These drugs are available as over the counter as well as prescription.

Market Size By Product Type

Market Size By Product Type
  • Analgesics
  • Antiplatelet agents
  • Vasodilators
  • Thrombolytics and anti-thrombotic agents
  • Glycoprotein IIb/IIIa inhibitors
  • Β adrenergic blockers
  • Angiotensin receptor antagonists
  • Angiotensin converting enzyme inhibitors
  • Top Key Players

    Myocardial Infarction Market Share of Key Players

    Myocardial Infarction Market Share of Key Players
    Apotex Inc. AstraZeneca Bayer AG Boehringer-Ingelheim Bristol-Myers Squibb Company Daiichi Sankyo Co. Ltd. Mylan N.V. Novartis AG Par Pharmaceutical Companies Inc. Pfizer Inc. Others

    Frequently Asked Questions (FAQs)

    What is the estimated growth rate (CAGR) of the Myocardial Infarction Market?
    Myocardial Infarction Market size will grow at approx. CAGR of 8% during the forecast period.
    Some of the top prominent players in Myocardial Infarction Market are, Apotex Inc., AstraZeneca, Bayer AG, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Daiichi Sankyo Co. Ltd., Mylan N.V., Novartis AG, Par Pharmaceutical Companies Inc., Pfizer Inc., etc.
    North America has held a dominant position in the Myocardial Infarction Market, with the largest market share.
    The region with the most rapid expansion in the Myocardial Infarction Market is Europe.
    The global Myocardial Infarction Market report is segmented as follows: By Product Type, By Distribution Channel


    We are featured on :